In the phase III ADMIRAL trial, comparing gilteritinib treatment to salvage chemotherapy in FLT3‐ITD mutated relapsed/refractory AML patients, the median overall survival was moderately improved from 5.3 months in the control arm to 9.3 months in the experimental arm [26]. The gene discussed is FLT3; the disease is acute myeloid leukemia.